国药控股：医药零售领衔，药械分销结构优化-20260324

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 22.53 [1][5] Core Views - The company reported a revenue of RMB 575.2 billion for 2025, a decrease of 1.6% year-on-year, and a net profit of RMB 7.16 billion, an increase of 1.5% year-on-year, which aligns with market expectations. The revenue and profit growth showed marginal improvement compared to the first three quarters of 2025, primarily due to resilient performance in the pharmaceutical and medical device distribution sectors, as well as effective cost control measures [1][5] - For 2026, the company is expected to maintain positive net profit growth, driven by continued structural optimization in pharmaceutical and medical device distribution and improved operational efficiency in retail [1] Summary by Sections Pharmaceutical Distribution - The pharmaceutical distribution segment generated revenue of RMB 435.4 billion in 2025, down 2.02% year-on-year, with an operating profit margin of 2.73%, remaining stable compared to the previous year. The outlook for 2026 is optimistic, supported by ongoing optimization of product categories and strengthening direct sales to high-tier hospitals and retail terminals [2] Medical Device Distribution - The medical device distribution segment reported revenue of RMB 115.5 billion in 2025, also down 2.02% year-on-year, primarily due to intensified procurement policies. The segment is expected to benefit from structural adjustments in 2026, including enhanced management of payment terms and an increased focus on high-value-added businesses [3] Retail Business - The retail business achieved revenue of RMB 38.4 billion in 2025, a growth of 6.67% year-on-year, becoming the leading growth segment for the company. The operating profit margin improved to 1.56%, driven by cost control measures and a significant reduction in losses for the Guoda Pharmacy [4] Profit Forecast and Valuation - The company is projected to have an EPS of RMB 2.50, RMB 2.71, and RMB 2.89 for the years 2026, 2027, and 2028 respectively. The target price remains at HKD 22.53, based on an 8.2x PE ratio for 2026, which is in line with comparable companies [5][10]